

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Deucravacitinib for treating moderate to severe plaque psoriasis

Draft scope

**Draft remit/appraisal objective**

To appraise the clinical and cost effectiveness of deucravacitinib within its marketing authorisation for treating moderate to severe plaque psoriasis.

**Background**

Plaque psoriasis is an inflammatory skin condition characterised by an accelerated rate of turnover of the upper layer of the skin (epidermis). This leads to an accumulation of skin cells forming raised plaques on the skin. These plaques can be flaky, scaly, itchy and red or a darker colour to the surrounding skin. Plaque psoriasis may affect the scalp, elbows, limbs and trunk and sometimes the face, groin, nails, armpits or behind the knees. Although it is a chronic, persistent, severe condition, its course may be unpredictable, with flare-ups and remissions. In people with darker skin the appearance of psoriasis may be less obvious, and severity may be underestimated.

Psoriasis is generally graded as mild, moderate or severe and takes into account the location, surface area of skin affected and the impact of the psoriasis on the person. The Psoriasis Area and Severity Index (PASI) is an index of disease severity in adults and takes into account the size of the area covered with psoriasis as well as redness, thickness and scaling. In addition, the Dermatology Life Quality Index (DLQI) is a validated tool that can be used to assess the impact of psoriasis on physical, psychological and social wellbeing.

The prevalence of psoriasis in the United Kingdom is estimated to be between 1.3% and 2.2%.<sup>1</sup> About 90% of people with the condition have plaque psoriasis and about 20% have moderate to severe disease (15% moderate, 5% severe),<sup>2</sup> equating to approximately 104,000 to 176,000 adults in England.<sup>3</sup>

There is no cure for psoriasis but there is a wide range of topical and systemic treatments that can manage the condition. Most treatments reduce the severity of psoriasis flares rather than prevent episodes. Psoriasis has to be treated continually and on a long-term basis. NICE clinical guideline 153 on psoriasis recommends that people with psoriasis should be offered topical therapies such as corticosteroids, vitamin D and vitamin D analogues. For people in whom topical therapy does not alleviate symptoms, the guideline recommends phototherapy (broad- or narrow-band ultraviolet B light) and psoralen with ultraviolet A phototherapy (PUVA). The guideline recommends systemic non-biological therapies (such as, as ciclosporin, methotrexate and acitretin) for people whose psoriasis:

- cannot be controlled with topical therapy **and**
- has a significant impact on physical, psychological or social wellbeing **and**
- one or more of the following apply:

- psoriasis is extensive **or**
- psoriasis is localised and associated with significant functional impairment and/or high levels of distress **or**
- phototherapy has been ineffective, cannot be used or has resulted in rapid relapse.

NICE technology appraisal guidance 103, 146, 180, 350, 419, 442, 475, 511, 521, 574, 575, 596 and 723 recommend etanercept, adalimumab, ustekinumab, secukinumab, apremilast, ixekizumab, dimethyl fumarate, brodalumab, guselkumab, certolizumab pegol, tildrakizumab, risankizumab, and bimekizumab respectively, as treatment options for adults with severe psoriasis (as defined by a total PASI score of 10 or more and a DLQI score of more than 10) whose disease has not responded to, or who are intolerant to or contraindicated to standard systemic therapies such as ciclosporin, methotrexate, acitretin and PUVA.

Technology appraisal guidance 134 recommends infliximab as a treatment option for adults with very severe psoriasis (as defined by a total PASI score of 20 or more and a DLQI score of more than 18) whose disease has not responded to, or who are intolerant to or contraindicated to standard systemic therapies. Biosimilar products of some biological therapies are available for use in the NHS.

**The technology**

Deucravacitinib (brand name unknown, Bristol Myers Squibb) is a tyrosine kinase 2 (TYK2) inhibitor which binds to the pseudo-kinase domain on TYK2 and selectively blocks the TYK2 enzyme targeting specific cytokine pathways. It is administered orally.

Deucravacitinib does not currently have a marketing authorisation in the UK for treating moderate to severe plaque psoriasis. It has been studied in clinical trials compared with apremilast or placebo in adults with moderate to severe plaque psoriasis.

<b>Intervention(s)</b>	Deucravacitinib
<b>Population(s)</b>	Adults with moderate to severe plaque psoriasis
<b>Comparators</b>	<p>If systemic non-biological treatment or phototherapy is suitable:</p> <ul style="list-style-type: none"> <li>• Systemic non-biological therapies (including methotrexate, ciclosporin and acitretin)</li> <li>• Phototherapy with or without psoralen</li> </ul> <p>For people with severe or very severe psoriasis for whom systemic non-biological treatment (including methotrexate, ciclosporin and acitretin) and phototherapy are inadequately effective, not tolerated or contraindicated:</p> <ul style="list-style-type: none"> <li>• TNF-alpha inhibitors (adalimumab, etanercept, infliximab [for very severe plaque psoriasis, as defined by a total PASI of 20 or more, and a DLQI of more</li> </ul>

	<p>than 18] and certolizumab pegol)</p> <ul style="list-style-type: none"> <li>• IL-17 family inhibitors or receptor inhibitors (brodalumab, ixekizumab, secukinumab and bimekizumab)</li> <li>• IL-23 inhibitors (guselkumab, tildrakizumab and risankizumab)</li> <li>• IL-12/IL-23 inhibitors (ustekinumab)</li> <li>• Apremilast</li> <li>• Dimethyl fumarate</li> <li>• Best supportive care.</li> </ul>
<p><b>Outcomes</b></p>	<p>The outcome measures to be considered include:</p> <ul style="list-style-type: none"> <li>• severity of psoriasis</li> <li>• psoriasis symptoms, such as itch on the following areas: face, scalp, nails and joints, and other difficult-to-treat areas including the hands, feet and genitals</li> <li>• mortality</li> <li>• response rate</li> <li>• duration of response</li> <li>• relapse rate</li> <li>• adverse effects of treatment</li> <li>• health-related quality of life.</li> </ul>
<p><b>Economic analysis</b></p>	<p>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p> <p>The availability of any commercial arrangements for the intervention, comparator and subsequent treatment technologies will be taken into account.</p>

<p><b>Other considerations</b></p>	<p>Where the evidence allows, the following subgroups will be considered:</p> <ul style="list-style-type: none"> <li>• previous use of phototherapy and systemic non-biological therapy</li> <li>• previous use of biological therapy</li> <li>• severity of psoriasis (moderate, severe).</li> </ul> <p>Where the evidence allows, sequencing of different drugs and the place of deucravacitinib in such a sequence will be considered.</p> <p>The availability and cost of biosimilar products should be taken into account.</p> <p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p>
<p><b>Related NICE recommendations and NICE Pathways</b></p>	<p><b>Related Technology Appraisals</b></p> <p><a href="#">‘Risankizumab for treating moderate to severe plaque psoriasis’</a> NICE technology appraisals guidance 596. Review date: August 2022.</p> <p><a href="#">‘Tildrakizumab for treating moderate to severe plaque psoriasis’</a> NICE technology appraisals guidance 575. Review date: April 2022.</p> <p><a href="#">‘Certolizumab pegol for treating moderate to severe plaque psoriasis’</a> NICE technology appraisals guidance 574. Review date: April 2022.</p> <p><a href="#">‘Bimekizumab for treating moderate to severe plaque psoriasis’</a> (2021) NICE technology appraisals guidance 723. Publication date: September 2021.</p> <p><a href="#">‘Guselkumab for treating moderate to severe plaque psoriasis’</a> (2018) NICE Technology Appraisal 521. Review date: TBC.</p> <p><a href="#">‘Brodalumab for treating moderate to severe plaque psoriasis’</a> (2018) NICE Technology Appraisal 511. Review date: TBC.</p> <p><a href="#">‘Dimethyl fumarate for treating moderate to severe plaque psoriasis’</a> (2017) NICE Technology Appraisal 475. Review date: TBC.</p> <p><a href="#">‘Ixekizumab for treating moderate to severe plaque psoriasis’</a> (2017) NICE Technology Appraisal 442. Review date: TBC.</p> <p><a href="#">‘Apremilast for treating moderate to severe psoriasis [rapid review of technology appraisal guidance 368]’</a> (2016) NICE Technology Appraisal 419. Review date: TBC.</p> <p><a href="#">‘Secukinumab for treating moderate to severe plaque psoriasis’</a></p>

	<p><a href="#">psoriasis</a>' (2015) NICE Technology Appraisal 350. Static list.</p> <p><a href="#">'Ustekinumab for the treatment of adults with moderate to severe psoriasis'</a> (2009) NICE Technology Appraisal 180. Static list.</p> <p><a href="#">'Adalimumab for the treatment of adults with psoriasis'</a> (2008) NICE Technology Appraisal 146. Static list.</p> <p><a href="#">'Infliximab for the treatment of adults with psoriasis'</a> (2008) NICE Technology Appraisal 134. Static list.</p> <p><a href="#">'Etanercept and efalizumab for the treatment of adults with psoriasis'</a> (2006) NICE Technology Appraisal 103. Static list. Note: guidance for efalizumab has now been withdrawn.</p> <p><b>Related Guidelines</b></p> <p><a href="#">'Psoriasis: assessment and management'</a> (2012) NICE guideline 153. No new evidence identified in June 2017. Review date to be confirmed.</p> <p><b>Related Interventional Procedures</b></p> <p><a href="#">'Grenz rays therapy for inflammatory skin conditions'</a> (2007) NICE interventional procedures guidance 236.</p> <p><b>Related Quality Standards</b></p> <p><a href="#">'Psoriasis'</a> (2013) NICE quality standard 40.</p> <p><b>Related NICE Pathways</b></p> <p><a href="#">'Psoriasis'</a> (2012; updated 2021) NICE Pathway.</p>
<p><b>Related National Policy</b></p>	<p>The NHS Long Term Plan, 2019. <a href="#">NHS Long Term Plan</a></p> <p>NHS England (2018/2019) <a href="#">NHS manual for prescribed specialist services (2018/2019)</a> Chapter 61: Highly specialist dermatology services.</p> <p>Department of Health and Social Care, NHS Outcomes Framework 2016-2017: Domains 1 - 5. <a href="https://www.gov.uk/government/publications/nhs-outcomes-framework-2016-to-2017">https://www.gov.uk/government/publications/nhs-outcomes-framework-2016-to-2017</a></p>

**Questions for consultation**

Have all relevant comparators for deucravacitinib been included in the scope?

Which treatments are considered to be established clinical practice in the NHS for moderate to severe plaque psoriasis?

Are the outcomes listed appropriate?

Are the subgroups suggested in 'other considerations' appropriate? Are there any other subgroups of people in whom deucravacitinib is expected to be more clinically effective and cost effective or other groups that should be examined separately?

How widespread is the use of biosimilar products in clinical practice?

Where do you consider deucravacitinib will fit into the existing NICE pathway, [Psoriasis](#)?

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope:

- could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which deucravacitinib will be licensed;
- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;
- could have any adverse impact on people with a particular disability or disabilities.

Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts.

Do you consider deucravacitinib to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a 'step-change' in the management of the condition)?

Do you consider that the use of deucravacitinib can result in any potential significant and substantial health-related benefits that are unlikely to be included in the QALY calculation?

Please identify the nature of the data which you understand to be available to enable the Appraisal Committee to take account of these benefits.

To help NICE prioritise topics for additional adoption support, do you consider that there will be any barriers to adoption of this technology into practice? If yes, please describe briefly.

NICE intends to appraise this technology through its Single Technology Appraisal (STA) Process. We welcome comments on the appropriateness of appraising this topic through this process. (Information on the Institute's Technology Appraisal processes is available at <http://www.nice.org.uk/article/pmg19/chapter/1-Introduction>).

NICE has published an addendum to its guide to the methods of technology appraisal (available at <https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/methods-guide-addendum-cost-comparison.pdf>), which states the methods to be used where a cost comparison case is made.

- Would it be appropriate to use the cost comparison methodology for this topic?

- Is the new technology likely to be similar in its clinical efficacy and resource use to any of the comparators?
- Is the primary outcome that was measured in the trial or used to drive the model for the comparator(s) still clinically relevant?
- Is there any substantial new evidence for the comparator technology/ies that has not been considered? Are there any important ongoing trials reporting in the next year?

### References

1. Parisi R, Griffiths CEM, Ashcroft DM (2011) Systematic review of the incidence and prevalence of psoriasis. *British Journal of Dermatology* 165: e5.
2. Menter A, Korman NJ, Elmets CA et al. (2011) [Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.](#) *J Am Acad Dermatol* 2011; 65:137–74.
3. Office for National Statistics (2020) [Population Estimates for UK, England and Wales, Scotland and Northern Ireland mid-2020.](#) Accessed November 2021.